Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Lancet Neurol
; 20(12): 1027-1037, 2021 12.
Article
in En
| MEDLINE
| ID: mdl-34800400
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Glycogen Storage Disease Type II
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adolescent
/
Humans
Language:
En
Journal:
Lancet Neurol
Journal subject:
NEUROLOGIA
Year:
2021
Document type:
Article